To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
NCT ID: NCT06315270
Last Updated: 2024-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2024-03-20
2029-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
NCT06611072
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
NCT06846424
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
NCT01000259
Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR Inhibitors
NCT05640024
Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer
NCT04072263
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group (ECOG) physical strength status (PS) score of 0 or 1;
* Cooperation in the treatment process by providing clinicopathological data and imaging data required for the study process;
* Cooperate with follow-up visits and collection of node blood for clinical efficacy assessment, and agree to use the test data for subsequent research and product development.
* The initial and follow-up treatment processes are in accordance with NCCN guidelines;
Exclusion Criteria
* Splenectomy patients;
* Patients with contraindications to radiotherapy;
* Any other patients who, in the judgement of the investigator, may have poor compliance with the procedures and requirements of the study;
* Unacceptable or unavailable means of assessing specified efficacy such as imaging;
* Vaccination within 2 months; antibiotics for infection within 2 weeks; history of blood transfusion within 2 weeks;
* Long-term use of recombinant human erythropoietin, recombinant human interleukin, Ricodin tablets and other drugs affecting the composition of blood cells;
* Severe organ dysfunction;
* Infectious diseases such as immunodeficiency syndrome, active tuberculosis, HIV infection, and other infectious diseases not suitable for participation;
* Pre-cancerous diseases of the blood, such as myelodysplastic syndromes;
* Have received immunosuppressive therapy within 2 weeks;
* Suffering from blood clotting disorders.
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Hospital of Jilin University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24K040-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.